Vyome shares surge 13.05% intraday after securing $5.29M in minimal dilution funding for VT-1953 Phase 3 trials.

Vyome Holdings, Inc. (Nasdaq: HIND) surged 13.05% intraday after announcing it successfully funded its VT-1953 Phase 3 study using its At-The-Market facility, avoiding higher-dilution alternatives. The company sold 1.09 million shares at a 59.2% premium to the prior day’s close, generating $5.29 million in net proceeds with only 15% dilution. This move secured sufficient liquidity to deliver interim Phase 3 results for its MFW drug candidate by mid-2027 and positioned the firm to advance its immuno-inflammatory pipeline without compromising shareholder value. Management emphasized the strategic choice to reject funding offers with warrants or restrictive terms, underscoring confidence in VT-1953’s $1 billion third-party valuation post-trial completion. The announcement reinforced investor optimism about the company’s capital efficiency and progress toward key clinical milestones.